Ferritin Assay

Home - Randox Reagents - Page 3

Ferritin Assay

Reagent | Ferritin

The Most Sensitive and Specific Diagnostic Test for Iron Deficiency

Benefits of Ferritin

Exceptional correlation

A correlation coefficient of r=0.99 was displayed when the Randox ferritin assay was compared to commercially available methods.

Limited interference

The Randox ferritin assay has shown to have limited interference from bilirubin, haemoglobin and triglycerides.

Applications available

Applications available detailing instrument-specific settings for the convenient use of the Randox ferritin assay on a variety of clinical chemistry analysers.

Excellent stability

The Randox ferritin assay is stable to expiry when stored at +2oC to +8oC.

Calibrator and controls available

Calibrator and controls available offering a complete testing package.

Ordering Information

Cat NoSize
FN3452R1 1 x 40ml (L)
R2 1 x 20ml
EnquireKit Insert RequestMSDSBuy Online
FN3888R1 3 x 20ml (L)
R2 3 x 11ml
EnquireKit Insert RequestMSDSBuy Online
FN8037 R1 4 x 16.2ml
R2 4 x 10.2ml
EnquireKit Insert RequestMSDSBuy Online
(L) Indicates liquid option

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

Diagnostic Uses

  • Physiological Significance
  • Iron Deficiency
  • Still's Disease
  • Sepsis
  • cHL
  • COVID-19

Ferritin is an iron storage protein. It is the primary iron storage mechanism and is critical to iron homeostasis. As an iron store, ferritin has two roles 1.

  1. Provides a reserve of iron, which can be transported for the synthesis of molecules such as cytochromes, haemoglobin and iron-sulphur compounds.
  2. Safe-guards cells, DNA, lipids and proteins from the potential toxic effects of iron.

Ferritin is a vital component of iron homeostasis. It acts as as a ferroxidase, converting Fe(II) to Fe(III) as iron is internalised and sequestered in the ferritin mineral core. Iron is toxic in cellular systems due to its capacity to generate reactive oxygen species (ROS) which directly damages cells, DNA, lipids and proteins 1.

Iron deficiency without anaemia is a diagnostic challenge, as it commonly goes unrecognised for a long period of time as the patient is asymptomatic. Ferritin is the most sensitive and specific test used in the diagnosis of iron deficiency, especially when a patient presents with symptoms of iron deficiency anaemia, but their full blood count is normal 2.

Adult onset Still’s Disease (AOSD) is a rare systemic inflammatory disorder characterised by arthritis, fever and a typical skin rash. Elevated ferritin levels have been observed in 89% of patients with AOSD, with five times the normal level observed in over half of patients 3.

Elevated ferritin levels is associated with a poor outcome in patients with sepsis and can be used as a predictive marker of mortality along with current prognostic scores 4. Elevations of both ferritin and CRP during hospitalisation was associated with the highest mortality, followed by elevations of either biomarker alone (fig. 1) 5.

Fig. 1. Risk contingency table for mortality and organ dysfunction based on cut-points for C-reactive protein and ferritin and patients’ maximum value for each biomarker 5
Fig. 1. Risk contingency table for mortality and organ dysfunction based on cut-points for C-reactive protein and ferritin and patients’ maximum value for each biomarker

Data is displayed as n / N (%) for mortality outcomes

*Significant difference in high/intermediate versus low risk quadrants; {<0.001 by Mann-Whitney test PELOD2, Pediatric Logistic Organ Dysfunction Score 2

Ferritin is the most important acute phase reactant in the prediction of classical Hodgkin lymphoma (cHL). Ferritin correlates with the inflammatory activity of the cHL microenvironment, which could explain its prognostic impact. Elevated ferritin levels are associated with clinical features of aggressive disease and poor prognosis in cHL patients 6.

As an acute phase reactant, ferritin levels increase during inflammation and infection. Several studies have indicated that elevated ferritins levels were confirmed in the majority of hospitalised patients with COVID-19, approximately 60%. In the critically ill COVID-19 patients, extremely elevated ferritin concentrations were recorded, which could be attributed to a cytokine storm and secondary haemophagocytic lymphohistiocytosis (a hyperinflammatory syndrome associated with multiorgan failure) 7.

Specific Protein Calibrator

Specific Protein Control

Specific Protein EQA


Albumin Assay

Reagent | Albumin

A Marker of Hepatic Dysfunction

Benefits of the Randox Albumin Assay

Excellent precision

The Randox albumin assay displayed a within run precision of < 1.97%.

Calibrator and controls available

Calibrator and controls available for a complete testing package.

Working Stability

Working reagent stable up to 3 months when stored at +15oC to +25oC.

Flexibility

Liquid and Lyophilised Reagents available for greater customer choice.

Applications available

Applications available detailing instrument-specific settings for the convenient use of the Randox albumin assay on a variety of clinical chemistry analysers.

Ordering information

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

Cat NoSize
AB3626 x 13.5ml (S)EnquireKit Insert RequestMSDSBuy Online
AB38009 x 51ml (L)EnquireKit Insert RequestMSDSBuy Online
AB80004 x 68ml (L)EnquireKit Insert RequestMSDSBuy Online
AB83014 x 20ml (L)EnquireKit Insert RequestMSDSBuy Online
(S) Indicates standard included in kit

(L)
Indicates liquid reagent

Clinical Significance

  • PHYSIOLOGICAL SIGNIFICANCE
  • MORTALITY
  • DIABETES
  • HEPATIC FUNCTION
  • COVID-19

Albumin is the most abundant circulating protein found in plasma, representing approximately half of the total protein content in health human plasma. Synthesised by liver hepatocytes, it is rapidly excreted into the bloodstream, approximately 10gm – 15gm per day, with little remaining in the liver 1. It is responsible for the maintenance of colloidal osmotic pressure, provision of the majority of plasma antioxidant activity, and the binding of a variety of compounds 2.

A correlation between serum albumin concentrations and ill-health has been identified, with an astonishingly strong inverse correlation between serum albumin and mortality risk 2. The association of it with other confounding variables increase mortality (fig 1). The concentration is related to the rates of synthesis and catabolism, but also influenced by state of hydration, lymphatic return, external losses (burns), and rates of transcapillary escape. In starvation, both the synthesis and catabolism fall, whereas in nephrotic syndrome, synthesis rises and catabolism falls 3.

Fig. 1. Potential associations between serum albumin and mortality 3
Fig. 1. Potential associations between serum albumin and mortality

A direct, casual relationship between serum albumin and mortality is represented by arrow a or the sequence b, a. A non-casual, confounding relationship is represented by arrows b and c. A co-causal relationship is represented by arrows a and c.

Low circulating albumin is associated with an adverse metabolic profile characterised by increased adipose tissue inflammation, glucose concentrations, and adiposity. It inversely correlates with type 2 diabetes mellitus (T2DM) risk 4. Moreover, serum albumin concentrations are inversely correlated with the risk of ketosis in hospitalised patients with T2DM and may require the early initiation of insulin therapy to prevent complications. It is a promising prognostic marker in hospitalised diabetic patients with acute hyperglycaemia 5.

Low levels of serum albumin is common in cirrhosis and is associated with a reduced survival rate. In this setting, the native isoform can be severely reduced as a result of several post-transcriptional changes that impair the non-oncotic properties of the molecule 6.

Hypoalbuminemia status has been associated with the critically ill and mortality across several clinical settings. Hypoalbuminemia can potentially lead to the early recognition of severe disease associated with COVID-19 and can assist clinicians in making informed decisions for their patients 7.

Related products

Clinical Chemistry Calibrator

Clinical Chemistry Control

Clinical Chemistry EQA


Third Party Diagnostic Assays

Diagnostic Reagents

Randox offer over 100 diagnostic reagents covering more than 100 disease markers. Our test panels include cardiology, lipids, specific proteins, therapeutic drug monitoring, antioxidants, diabetes and veterinary diagnostics. Randox reagents are internationally recognised as being of the ‘highest quality’, delivering accurate traceability and precise patient results.

Key Benefits

Superior Performance

Superior Methodology

Our methodologies ensure accurate and reliable results compared to traditional methods.

In Vitro Diagnostics Testing

Comprehensive Test Menu

A broad testing panel of over 100 diagnostic assays including routine as well as niche reagents unique to Randox

Correlation

Excellent Correlations

Excellent correlations to gold standard & commercial methods providing confidence in patient results

Applications Available

Applications Available

Applications are available for a range of clinical chemistry analysers offering convenience of use

Dedicated bottle

Dedicated Reagent Bottles

Availability of reagents in instrument dedicated bottles, reducing operator time

Reduce costs

Reduce Costs

Versatile test menu enabling laboratories to reduce costs with in-house testing

Testing Panels

Randox provide reagents that are applicable for a wide range of testing panels including the below.

Need more information?

Download the Randox Reagents Brochure for more information or if you would like to get in touch please fill out our quick online enquiry form.

Reagent Instructions

Product Inserts are available to download on our online portal

If you are using the online portal for the first time, you must first register your details using the link provided. Click ‘Request Access’, and submit your details to receive a login.

Reagents by instrument

Randox develop and manufacture reagents that can be used on a variety of clinical chemistry analysers. Randox also supply the applications detailing settings for these instruments. All kits are produced to international standard and have ISO 13485 accreditation. See reagents available for the instruments below.

The A-Z Range of Randox Reagents

Select an assay below for more information. Our reagents are suitable for open channels on third party instruments.

Email Us

Get in touch with Randox via email at reagents@randox.com

Need Instructions?

Kit Inserts are available to download for free on our online portal

Buy Online

Order your reagents kits online by visiting our online store 


Lipase Reagent

Reagent | Lipase

Key Benefits of the Randox Lipase Assay

Excellent precision

The Randox lipase assay displayed a precision of  <5% CV.

Exceptional correlation

The Randox lipase assay displayed an exceptional correlation coefficient of r=1.00 when compared against other commercially available methods.

Fully automated protocols

Fully automated protocols are available for a variety of clinical chemistry analysers.

Further Benefits of the Randox Lipase Assay

Colorimetric method.

Liquid ready-to-use format for convenience and ease-of-use.

Applications available detailing instrument-specific settings for the convenient use of the Randox lipase assay on a wide range of clinical chemistry analysers.

Cat NoSize
LI3837R1 3 x 9ml (L)
R2 3 x 6ml
EnquireKit Insert RequestMSDSBuy Online
LI7979R1 6 x 20ml (L)
R2 3 x 20ml
EnquireKit Insert RequestMSDSBuy Online
LI8050R1 4 x 16.2ml (L)
R2 4 x 10ml
EnquireKit Insert RequestMSDSBuy Online
(L) Indicates liquid option

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

About Lipase Testing

  • Clinical Significance
  • Physiological Significance

Elevated lipase concentrations 3-to-4-fold greater than the upper normal limit is indicative of pancreatitis, however, the degree of elevations does not correlate with the severity of the disease 2, 3.

In pancreatic dysfunction, lipase concentrations rise between 4 and 6 hours, peaking at 48 hours and returning to baseline within 8 to 14 days. It has a half-life of 6.7 to 13.7 hours in plasma. The half-life of amylase (another assay utilised in the diagnosis of pancreatic dysfunction) is less, however, lipase is filtered by the glomerulus and reabsorbed by the tubules which may contribute towards the longer half-life of lipase.

Lipase offers a few advantages over amylase including: a slightly better specificity, greater sensitivity for patients presenting late, due to the longer half-life, and greater sensitivity in alcoholic pancreatitis 4.

Furthermore, for prolonged longitudinal injuries, lipase activity tends to be more sensitive compared to amylase as lipase concentrations within the zymogen granules are approximately 4.5 times than those of amylase. Consequently, recurring injuries are more likely to be recognised due to the leakage of lipase into the bloodstream. Moreover, lipase concentrations are less affected by intestinal injury or renal dysfunction compared to amylase 2.

Derived from zymogen granules of pancreatic acinar cells, lipase is involved in the digestion of lipids for the subsequent absorption in the small intestine 1, 2. The pancreas is located in the anterior abdominal cavity adjacent to the liver, duodenum and stomach to allow the secretion of digestive enzymes into the small intestine, and to convert ingesta into absorbable lipids, carbohydrates and proteins. The exocrine pancreas provides a microenvironment for pancreatic islet cells. The pancreatic islet cells provide the embedded endocrine function of the pancreas which in turn enables the hepatic and peripheral tissues to modulate blood glucose levels and other functions 2.

Clinical Chemistry Panel

For more information or to view more reagents within the clinical chemistry panel, please click here

Veterinary Panel

For more information or to view more reagents within the veterinary panel, please click here


Medlab Middle East

Join us for Medlab Middle East 2020!

 

Randox Laboratories will be attending Medlab Middle East form the 3rd February – 6th February 2020. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.

Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Dubai International Convention & Exhibition Centre at stand Z5.B10.

 

New Products

  • Serology Controls
  • Stroke Biochip
  • Lipoprotein(a)
  • H-FABP in CSA-AKI Testing
  • Acusera Verify
  • Evidence+

Acusera Infectious Disease Serology Controls

Randox Quality Control are pleased to announce the launch of our new Infectious Disease Serology Internal Quality Controls. Our portfolio includes Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more.

All samples are provided in a user-friendly, liquid ready-to-use format. This significantly reduces preparation time and the risk of pipetting errors.

There is approximately 1 million people in the USA living with HIV and around 15% of them are unaware they are infected (CDC, March 2019). Furthermore, the Centers for Disease Control and Prevention (CDC) estimate that around 39,000 new HIV infections are reported per year.

The impact of not only HIV but all infectious diseases is getting much greater. Therefore, laboratories now play a much more important role in providing accurate test results. This is a key component in controlling the spread of infections.

Reporting a false positive result has its own obvious implications, however, what about the consequences of reporting a false negative. This can be just as devastating to a person in terms of the treatment they will receive and even personal lifestyle changes for the patient in question.

Randox Stroke Biochip

The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.

Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.

Benefits of the Randox Stroke Biochip

> Multiplex biochip for rapid stroke classification in under 30 minutes from a single plasma sample

> Complements and enhances existing CT scanning ensuring fast and accurate diagnosis

> Fast and accurate diagnostic classification between ischaemic and haemorrhagic stroke

> Simple 2 step process from sample entry to results

> Ensures better outcomes guaranteeing timely therapeutic intervention

Lipoprotein(a) [Lp(a)]

 Lipoprotein(a) [Lp(a)] is described as “the most complex and polymorphic of the lipoprotein particles” 1. The biggest challenge that exists surrounding Lp(a) measurement is the heterogeneity of the apo(a) isoforms. Standardisation across calibrators is vital as the repeated KIV-2 units in Lp(a) act as multiple epitopes. A lack of standardisation could result in the underestimation of Lp(a) associated CVD risk 2.

Lp(a) assays that are standardised to the WHO/IFCC reference material, transferring values from mg/dl to nmol/l are more uniformed. The Denka Seiken Lp(a) assay is the most reliable commercially available Lp(a) assay, because 2:

  1. The isoform size variations are reduced as a range of calibrators from separate pools of serum were used which covered a range of Lp(a) concentrations.
  2. The isoform size and concentrations are inversely correlated better matching calibrants with test samples.
  3. Methods based on the Denka Lp(a) assay, calibrated in nmol/l and traceable to the WHO/IFCC reference material produced an acceptable bias compared with the Northwest Lipid Metabolism and Diabetes Research Laboratory (NLMDRKL) gold standard method.

 

HEART UK advocate the widespread clinical utility of Lp(a) to refine the CVD risk assessment. In doing so, HEART UK developed ten statements on Lp(a) (Table 1) utilising the 2016 ACC/AHA Clinical Guideline Recommendation Classification System, to assess the strength of the recommendation and aid in guiding the phrasing of the recommendation 2.

Key Features of the Randox Lp(a) Assay

  • The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule and therefore suffers minimal size related bias providing more accurate and consistent results. The Randox Lp(a) kit is standardised to the WHO/IFCC reference material (IFCC SRM 2B) and is closest in terms of agreement to the ELISA reference method.
  • Five-point calibrator with accuracy-based assigned target values, and control are available, accurately reflecting the heterogeneity of the apo(a) isoforms present in the general population and offering a complete testing package.
  • Measuring units are available in nmol/l which is more uniformed and recommended by HEART UK.
  • Immunoturbidimetric method is highly sensitive and specific for the detection of Lp(a) in serum and plasma.
  • Excellent correlation co-efficient of r=0.995 when compared against other commercially available methods.
  • Excellent within run precision of <2.54%.
  • Liquid ready-to-use format for convenience and ease-of-use.
  • Applications available detailing instrument-specific settings for the convenient use of the Randox Lp(a) assay on a wide range of clinical chemistry analysers.

 

References

  1. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application . Journal of Lipid Research 2019; 57(): 526-537.
  2. Cegla J, Dermot R, Neely G, France M, Ferns G, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis 2019; 291(): 62-70.

H-FABP in CSA-AKI Testing

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a well-recognised postoperative complication of cardiac surgery and is the second most common cause of AKI in the ICU, occurring in up to 30% of patients. Higher pre-operative values of H-FABP were associated with a higher risk of developing AKI. Following adjustments of certain patient characteristics, the association of pre-operative H-FABP with the development of AKI remained significant. In fact, the researchers observed that a 1 unit increase in log H-FABP was associated with a 3-fold increase in the odds of developing AKI.

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

The new Evidence+

The fully automated Evidence+ analyzer is set to truly revolutionize laboratories worldwide. Continuing to provide high standards of quality, efficiency and reliability, the fully automated batch immunoanalyzer simultaneously detects multiple drugs and drug metabolites from a single sample.

The Evidence+ analyzer enables both efficient and cost-effective testing whilst providing accurate and reliable results to larger high throughput laboratories.

What can we offer?

  • Biosciences
  • Quality Control
  • EQA
  • QCMD
  • Qnostics
  • Reagents
  • Evidence Series
  • RX Series
  • Toxicology
vivalytic

Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.

Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.

Vivalytic

Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic  a unique space-saving, hygienic solution for Molecular Diagnostic testing.

Leading provider of true third-party controls

With over 390 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover, the availability of truly independent third-party controls coupled with the added advantages of highly accurate target values, excellent stability and unparalleled quality will enhance performance, save valuable time and minimize waste in any laboratory. Our comprehensive range of multi-analyte controls have been uniquely developed with user convenience in mind. By combining more than 100 parameters in a single vial, laboratories can significantly reduce the need for multiple, costly single analyte controls.

Online QC software with real-time peer group statistics

Designed to help you efficiently review QC data from multiple laboratory instruments on one centralized platform, Acusera 24.7 allows quick and easy identification of QC failures and emerging trends.

Unique access to live peer group updates will reduce time and money spent troubleshooting, helping you to instantly discover if an issue is isolated to your lab or a widespread problem. The added benefit of automatically generated statistics including Sigma Scores, Measurement Uncertainty & Total Error as well as fully interactive charts & reports will enable quick and easy performance monitoring.

Book a live demonstration for Acusera 24.7

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

RIQAS – The World’s Largest International PT scheme

With over 45,000 laboratory participants in more than 133 countries, the Randox International Quality Assessment Scheme (RIQAS) is truly the largest international PT provider in the world. Our comprehensive product offering currently covers over 360 parameters across 33 flexible programmes. Each RIQAS programme contains a unique combination of parameters meaning laboratories can significantly reduce the number of individual programmes required whilst increasing efficiency and reducing costs. Further benefits to a laboratory include accreditation to ISO 17043:2010, frequent reporting, reduced parameter options and access to comprehensive yet user-friendly reports.

QCMD is a world leading External Quality Assessment (EQA) / Proficiency Testing (PT) scheme, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases.

With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of molecular diagnostics.

Molecular Infectious Disease Controls

Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing. Supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, pharmaceutical and CRO organisations for over a decade.

Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.

Randox Reagents are internationally recognised as being of the highest quality, offering reliable and rapid results. Our product portfolio consists of 117 clinical chemistry assays, covering a range of testing panels, including: antioxidants, diabetes, cardiology and lipids, specific proteins, therapeutic drug monitoring and veterinary testing.

Randox are continuously striving to improve diagnostic solutions worldwide.  As a result, Randox have produced 29 niche and superior performance assays, including: 5th Generation Bile Acids, Adiponectin, Aldolase, Copper, Cystatin C, D-3-Hydroxybutyrate, G6PDH, H-FABP, Lipoprotein (a), NEFA, HDL Cholesterol, sdLDL Cholesterol, Total Antioxidant Status and Zinc.

Evidence series immunoassay analysers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

This multiplex system delivers an unrivalled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.

Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, antioxidants, veterinary and diabetes testing. Guaranteeing real cost savings through consolidation of routine and specialised tests onto a single platform, the RX series of analysers delivers excellence in patient care, offering unrivalled precision, accuracy and reliability.

RX misano

The RX misano semi-automated analyser has been developed with the user in mind by incorporating a responsive touch-screen display. The sleek ergonomic design boasts intuitive user-friendly software allowing for test menu personalisation and ease of use. The RX misano is capable of high standard, precise results at a competitive price per test.

RX monaco

The RX monaco is a fully automated solution for low to mid volume clinical chemistry testing offering the ultimate in convenience, performance and confidence. At optimal configuration, the RX monaco performs 170 tests per hour providing cost effective, high quality testing.

RX daytona +

The RX daytona+ is a fully automated, benchtop, clinical chemistry analyser capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyser in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivalled performance with direct HbA1c testing capabilities.

RX imola

The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyser with direct HbA1c testing capabilities. The RX imola is a fully automated system with random access and STAT sampling functionality, boosting productivity and saving time when it matters most

RX modena

Capable of performing up to 1,200 tests per hour, with direct HbA1c testing capabilities, the RX modena consolidates all your assay requirements onto one intuitive platform. The RX modena boasts icon based, interactive touch-screen technology adding a modern flair to your laboratory.

Find out more about Direct HbA1c
Book a demonstration of one of our analysers

Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.

Want to know more?

Contact us or book a meeting with us





Diabetes diagnosis with Randox Reagents

The prevalence of diabetes is steadily increasing across the world, with approximately 422million people worldwide with diabetes and is currently one of the leading causes of death in the world. A diabetes diagnosis comes in three forms; Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus and Gestational Diabetes. Each type of diabetes can have long-term, detrimental effects to your health if it is not controlled, with some of the key complications being heart disease, kidney damage, retinopathy and even limb amputations.

Diabetes can be controlled through maintaining a healthy diet and regular exercise, however in situations where complications occur, innovative testing can aid in the prevention and management of detrimental consequences to patients.  Randox Reagents offer a range of high performance and unique tests which can be used to manage complications of diabetes such as:

Diabetic Nephropathy

Kidney disease is a life threatening complication of diabetes, commonly called diabetic nephropathy in patients with diabetes. Around 40% of people with diabetes develop diabetic nephropathy, characterised through prolonged periods of high glucose levels in the blood. To effectively monitor diabetic nephropathy, it is essential to test cystatin C levels in patients, which is a useful indicator of renal function in patients where creatinine measurements are unreliable. Unlike creatinine, cystatin C does not have a ‘blind area’ – up to 50% of renal function can be lost before significant creatinine elevation occurs. This makes cystatin C capable of detecting early stage kidney dysfunction in patients with diabetic nephropathy.

Microalbumin testing is also important to identify patients with diabetic nephropathy approximately 5-10 years earlier than proteinuria tests, helping to reduce the incidence of end stage renal disease. This is because low albumin concentrations in the urine are the earliest market of renal damage and therefore enable preventative measures to be taken.

Metabolic Syndrome

Metabolic syndrome is a severe complications of uncontrolled diabetes which contains a number of conditions which occur together, increasing your risk of heart disease, stroke and diabetes. Metabolic syndrome can be monitored through measuring Non-Esterified Fatty Acids (NEFA), which are molecules released from triglycerides by the action of the enzyme lipase and are transported in the blood bound to albumin. NEFA contributes a small proportion of the body’s fat, however they provide a large part of its energy, with elevated concentrations having adverse effects on both carbohydrate and lipid metabolism.

With the global burden of diabetes rising year on year, diabetes complications monitoring has never been more important. Randox Reagents offer a wide range of innovative testing to laboratories, to help clinicians accurately diagnose and monitor diabetes complications.

 

Download our diabetes brochures to find out about our full range of diabetes reagents

Randox reagents are available for a wide range of clinical chemistry analysers. For more information, please contact reagents@randox.com